Prokaryotics, Inc., a Union, N.J.-based biopharmaceutical company engaged in the discovery and development of novel anti-infective drugs, has been awarded its second Small Business Innovation Research Grant (SBIR) valued at up to $2.3m.
The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) provided the award. The two-year agreement will fund research by Prokaryotics on a natural product cell wall synthesis inhibitor targeting antimicrobial-resistant Neisseria gonorrhoeae.
For the first phase of the grant (1 R44 AI138688-01A1), up to $300k funding will be used to support initial natural product isolation and microbiological activity evaluation. Contingent on the success of these studies, second phase funds up to $2m are additionally provided to support animal efficacy and pre-clinical studies.
Led by Terry Roemer, Ph.D., founder and chief scientific officer, and Keith Bostian, Acting CEO, Prokaryotics is a biopharmaceutical company focused on the discovery and development of novel antibiotic classes that target serious multi-drug resistant bacterial infections. Prokaryotics leverages a deep knowledge of bacterial physiology, innovative screening strategies, and scientific excellence necessary to discover and develop new classes of antibiotics targeting outer membrane biogenesis – the fundamental armor erected by bacteria to naturally withstand the effects of antibiotics.